Allergy

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

New data shows higher rates of cancer and cardiovascular disease deaths for patients with celiac disease.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Discussing an editorial in the Journal of Clinical Endocrinology & Metabolism with journal editor in chief Paul Stewart, MD.

What effect may professional athletes receiving asymptomatic tests have on the public perception of the coronavirus?

The three-year study represents the largest long-term kinetic immunotherapy trial.

The label update comes after findings have repeatedly shown an associated risk of neuropsychiatric events.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.

The FDA announced the switch of the 2 eyedrops, which took place through their RX-to-OTC program.

Nearly one dozen therapies have reached the psoriasis market, and the new standard is at least 90% skin clearance—an achievement previously unmet.

In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.

Are current methods and biomarkers viable, or are there better options to uncover?

In months, the US may have its first marketed peanut immunotherapies. How will pediatric patient management change?

An analysis of mepolizumab use shows fewer than 1% of prescribed patients are likely to use biologics concomitantly.

For what other indications, and in what regimens, are investigators assessing the drug class?

Certain diet-based comorbid conditions are more prevalent in food-allergic patients.

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.

A new survey shows more than 60% of adult patients with peanut allergy do not feel confident in managing their condition, despite taking preventive measures.

How can physicians train parents to trust immunotherapy—an allergen exposure they were previously told to avoid?

A growing patient population and burdens of physician shortage require specialists and primary care collaborate more and more.

Assessing a food allergy patient's overall diet during immunotherapy trials could unlock understanding how the microbiome affects the allergic reaction.

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.